Delivery Order SPE2DB20D1051-SPE2DB24FD8FX
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,252.28, is for the delivery of NALOXONE HCL 4 MG NASAL SPRAY 2S, a critical medication used to treat opioid overdose. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of March 24, 2025. The contract was not set aside for any specific...
- This federal contract award, valued at $1,838.72, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,567,999,320 units of Naloxone HCl 4 mg Nasal Spray, a critical medication used to treat opioid overdoses. This delivery order contract has a firm fixed-price pricing type and an ultimate completion date of April 23, 2025. Amerisourcebergen Drug Corp also...
- This federal contract award, valued at $2,667.47, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4566961838 - NALOXONE HCL 4 MG NASAL SPRAY 2S, a critical medication used for the treatment of opioid overdose. The contract is a Delivery Order with a Firm Fixed Price pricing type, and an ultimate completion date of January 17, 2025. Amerisourcebergen holds a...
- This federal contract award, valued at $1,755.41, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of NALOXONE HCL 4 MG NASAL SPRAY 2S, a critical medication used in the treatment of opioid overdose. The contract has an ultimate completion date of October 30, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $1,355.00 fixed-price delivery order is for the supply of NALOXONE HCL 4 MG NASAL SPRAY 2S, a critical medication used for the treatment of opioid overdose. The contract has an ultimate completion date of February 21, 2025. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This federal contract award, valued at $2,782.09, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,561,182,545 units of Naloxone HCL 4 mg Nasal Spray, a critical medication used to treat opioid overdoses. This is a firm fixed-price delivery order with a completion date of June 9, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a...
- This federal contract award, valued at $2,037.40, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order for 4,568,161,333 units of Naloxone HCl 4 mg Nasal Spray, a medication used to treat opioid overdose. The contract has a firm fixed-price pricing type and an ultimate completion date of May 7, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery...
- This federal contract award, valued at $2,718.08, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4567629382 ! NALOXONE HCL 4 MG NASAL SPRAY 2S, which are critical medical products used for the treatment of opioid overdoses. The contract has an ultimate completion date of March 20, 2025 and is a Firm Fixed Price Delivery Order. Amerisourcebergen also holds...
- This federal contract award, valued at $1,685.15, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4 mg Naloxone HCl nasal spray, a critical medication used to treat opioid overdoses. The contract has a period of performance through February 27, 2025 and utilizes a firm fixed-price pricing structure. The award is not associated with a set-aside program and represents an open competition....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,559.72 firm fixed-price delivery order is for the supply of Naloxone HCL 4 mg nasal spray, a critical medication used to reverse opioid overdoses. The contract has an ultimate completion date of October 29, 2024. AmerisourceBergen holds a large Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
- SPE2DB20D1051Indefinite Delivery Contract
- SPE2DB20D1051-SPE2DB24FD8FXDelivery Order
This federal contract award, with a ceiling value of $1,379.99, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation's Corporate Office division. The contract is for the delivery of 4564881464 - NALOXONE HCL 4 MG NASAL SPRAY 2S, a critical medication used to treat opioid overdoses. The award is a Delivery Order contract with a Firm Fixed Price pricing type, and it has an ultimate completion date of June 13, 2024. The contract is not associated with a set-aside designation. Amerisourcebergen Drug Corporation is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, including the Department of Defense (DoD) and Veterans Affairs (VA) healthcare systems. The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the DoD worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 6/12/24 |